WARNING LETTER

Date: March 6, 2020

TO: partner.services@jimbakkershow.com, website@jimbakkershow.com – James Bakker, The 

Jim Bakker Show

180 Grace Chapel Rd.

Blue Eye, MO 65611

RE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)

This is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade 

Commission (FTC) reviewed your website at the Internet address www.jimbakkershow.com on February

21, 2020 and February 13, 2020, respectively. We have also reviewed your social media page at 

https://www.facebook.com/jimbakkershow/, where you provide a link to your website 

www.store.jimbakkershow.com to purchase your products. The FDA has determined that your website 

offers products labeled to contain silver, such as “Silver Sol Liquid,” for sale in the United States and that 

these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-191 in people. FDA has 

determined that these products are unapproved new drugs sold in violation of the Federal Food, Drug, and 

Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under 

section 502 of the FD&C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these 

products into interstate commerce is prohibited under section 301(a) and (d) of the FD&C Act, 21 U.S.C. § 

331(a) and (d). 

The Secretary of Health and Human Services, under section 319 of the Public Health Service Act, 42 

U.S.C. § 247d, has determined that a public health emergency exists nationwide as a result of confirmed 

cases of COVID-19. Therefore, FDA is taking urgent measures to protect consumers from certain products 

that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose or cure COVID 

19 in people. We request that you take prompt action to cease the sale of such unapproved and 

unauthorized products for mitigation, prevention, treatment, diagnosis, or cure of COVID-19. 

Some examples of the claims on your website that establish the intended use of your products and 

misleadingly represent them as safe and/or effective for the treatment or prevention of COVID-19 include: 

• “But this influenza [sic] that is now circling the globe, you’re saying that Silver Solution would be 

effective? Well let’s say it hasn’t been tested on this strain of the coronavirus, but it’s been tested on 

other strains of the coronavirus, and has been able to eliminate it within 12 hours, totally eliminate 

it, kills it, deactivates it”

 1 COVID-19 is the official name for the disease that is causing the 2019 novel coronavirus outbreak, first identified in Wuhan, 

China.
Jim Bakker Show – (continued) Page 2 of 3 pages

[from your video entitled “A Close Look At What’s Not Being Said About the Coronavirus 

(Day 1)” at [44:48], https://jimbakkershow.com/watch/?guid=3861]

• “Silver Solution has been proven ... to kill every pathogen it has ever

been tested on ... and it can kill any of these known viruses ...”

• “So the virus, like the coronavirus that we’re talking about ... affects the lung tissue so what you 

can do ... put it straight ... in a nebulizer which then creates a steam and you breathe it in and it will 

go directly into your lungs where that virus is and any other infection”

“You should take immediate action to correct the violations cited in this letter. The violations cited in this 

letter are not meant to be an all-inclusive list. It is your responsibility to ensure that the products you sell 

are in compliance with the FD&C Act and FDA's implementing regulations. We advise you to review your 

websites, product labels, and other labeling and promotional materials to ensure that you are not 

representing your products for a COVID-19 related use for which they have not been approved by FDA, 

and that you do not make claims that misbrand the products in violation of the FD&C Act. Within 48 

hours, please send an email to COVID-19-Task-Force-CFSAN@fda.hhs.gov describing the specific steps 

you have taken to correct these violations. Include an explanation of each step being taken to prevent the 

recurrence of violations, as well as copies of related documentation. Failure to immediately correct the 

violations cited in this letter may result in legal action, including, without limitation, seizure and injunction. 

FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or 

authorized by FDA and that are being misleadingly represented as safe and/or effective for the treatment or 

prevention of COVID-19. Your firm will be added to a published list on FDA's website of firms and 

websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 

related products in violation of the FD&C Act. This list can be found at www.fda.gov/consumers/healthfraud-scams/fraudulent-coronavirus-disease-covid-19-products. Once you have taken corrective actions 

and such actions have been confirmed by the FDA, the published list will be updated to indicate that your 

firm has taken appropriate corrective action.

If you cannot complete corrective action within 48 hours, state the reason for the delay and the time within 

which you will complete the corrections. If you believe that your products are not in violation of the 

FD&C Act, include your reasoning and any supporting information for our consideration. 

If you are not located in the United States, please note that products that appear to be misbranded or 

unapproved new drugs are subject to detention and refusal of admission if they are offered for importation 

into the United States. We may advise the appropriate regulatory officials in the country from which you 

operate that FDA considers your product(s) listed above to be unapproved and misbranded products that 

cannot be legally sold to consumers in the United States. Please direct any inquiries to FDA at COVID-19-

Task-Force-CFSAN@fda.hhs.gov.

In addition, it is unlawful under the FTC Act, 15 U.S.C. 41 et seq., to advertise that a product can prevent, 

treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when 

appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they 

are made. To make or exaggerate such claims, whether directly or indirectly, through the use of a product 

name, website name, metatags, or other means, without rigorous scientific evidence sufficient to 

substantiate the claims, violates the FTC Act. 

There currently are no vaccines, pills, potions, lotions, lozenges or other prescription or over-the-counter 
Jim Bakker Show – (continued) Page 3 of 3 pages

products available to treat or cure coronavirus disease 2019 (COVID-19). Thus, the claims cited above are 

not supported by competent and reliable scientific evidence. You must immediately cease making all such 

claims. In addition, you are advised to review all claims for your products and immediately cease making 

claims that are not supported by competent and reliable scientific evidence. Violations of the FTC Act may 

result in legal action seeking a Federal District Court injunction and an order may require that you pay back 

money to consumers. Within 48 hours, please send an email to Richard Cleland, Assistant Director of 

the FTC’s Division of Advertising Practices, via electronic mail at rcleland@ftc.gov describing the specific 

actions you have taken to address the FTC’s concerns. If you have any questions regarding compliance 

with the FTC Act, please contact Mr. Cleland at 202-326-3088.

Sincerely,

William A. Correll

Director

Office of Compliance

Center for Food Safety

 and Applied Nutrition

 Sincerely,

 

 

 

 Richard A. Quaresima

 Acting Associate Director

 Division of Advertising Practices

 Federal Trade Commission